verucerfont

Verucerfont is a potent, selective small molecule antagonist of the corticotropin releasing factor receptor 1 (CRF1), developed by GlaxoSmithKline under license from Neurocrine Biosciences. It is orally available and brain penetrant. Verucerfont was investigated for the treatment of several stress-related disorders, including congenital adrenal hyperplasia (CAH), post-traumatic stress disorder (PTSD), alcoholism, major depressive disorder, irritable bowel syndrome, and social phobia. Its mechanism involves blocking CRF1 receptors to reduce adrenocorticotropic hormone (ACTH) release in response to chronic stress. While it showed promising neuroendocrine effects in preclinical models and some clinical studies—such as dampening HPA axis activation—it did not demonstrate efficacy in reducing alcohol craving or treating depression in human trials. Development for all indications has been discontinued[1][2][3][5][6][7].

Other names

verucerfontVERUCERFONT [INN]885220-61-1